guest ::
| Home > Publications database > Potential value of [68Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis. > print |
| Home > Publications database > Potential value of [68Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis. > print |
| 001 | 306585 | ||
| 005 | 20251127115918.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-025-07674-5 |2 doi |
| 024 | 7 | _ | |a pmid:41288692 |2 pmid |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02626 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Pabst, Kim M |0 0000-0002-9234-0795 |b 0 |
| 245 | _ | _ | |a Potential value of [68Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis. |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2025 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1764166889_3813577 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a epub |
| 520 | _ | _ | |a [68Ga]Ga-FAPI-46 has shown promise for urothelial cancer (UC) detection. This study evaluates its diagnostic value versus contrast-enhanced CT (ceCT) and 2-[18F]FDG PET in the largest bi-centric cohort to date.Patients with metastatic UC undergoing [68Ga]Ga-FAPI-46 PET at University Hospitals Munich or Essen were retrospectively reviewed. Detection rates were compared with ceCT on a regional basis (primary, lymph nodes, visceral organs, bone). SUVmax and SUVmean of two index lesions were recorded. In a sub-cohort, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET were compared on a lesion basis. Clinical follow-up and/or histopathology served as reference.Thirty-four patients underwent [68Ga]Ga-FAPI-46 PET/CT and ceCT, including 10 (29%) with additional 2-[18F]FDG PET/CT. Across 98 lesions (n = 65 regions), [68Ga]Ga-FAPI-46 PET detected n = 96 (98%) and ceCT n = 88 (90%), with mismatch findings in eight lymph nodes (PET positive/ceCT negative) and two visceral organs (ceCT positive/PET negative). In the subgroup comparison, 78 lesions were detected in total ([68Ga]Ga-FAPI-46: n = 72 (92%); 2-[18F]FDG: n = 78 (100%)). Tumour uptake was comparable (SUVmax [68Ga]Ga-FAPI-46 PET vs. 2-[18F]FDG: 10.2 (IQR, 1.9) vs. 8.0 (IQR, 3.3), p = 0.249), whereas [68Ga]Ga-FAPI-46 provided higher tumour-to-background ratios (Tumour-to-liver: 12.7 (IQR, 10.3) vs. 3.8 (IQR, 1.9), p = 0.046; tumour-to-spleen: 8.4 (IQR, 6.6) vs. 4.6 (IQR, 0.6), p = 0.016).[68Ga]Ga-FAPI-46 PET demonstrated higher regional detection rates than ceCT in UC patients, particularly for lymph node metastases. Compared to 2-[18F]FDG, it provided superior tumour-to-background contrast but detected slightly fewer lesions. [68Ga]Ga-FAPI-46 PET may complement established imaging in selected scenarios, although its role in routine UC staging remains investigational. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a 2-[18F]FDG-PET |2 Other |
| 650 | _ | 7 | |a CeCT |2 Other |
| 650 | _ | 7 | |a Detection efficacy |2 Other |
| 650 | _ | 7 | |a Urothelial carcinoma |2 Other |
| 650 | _ | 7 | |a [68Ga]Ga-FAPI-46 PET |2 Other |
| 700 | 1 | _ | |a Siegmund, Sophie C |b 1 |
| 700 | 1 | _ | |a Holzgreve, Adrien |b 2 |
| 700 | 1 | _ | |a Schmid, Hans P |b 3 |
| 700 | 1 | _ | |a Bartel, Timo |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Herrmann, Ken |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Küper, Alina T |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Aydogdu, Can |b 7 |
| 700 | 1 | _ | |a Kersting, David |b 8 |
| 700 | 1 | _ | |a Kesch, Claudia |b 9 |
| 700 | 1 | _ | |a Hadaschik, Boris A |b 10 |
| 700 | 1 | _ | |a Unterrainer, Marcus |b 11 |
| 700 | 1 | _ | |a Stief, Christian G |b 12 |
| 700 | 1 | _ | |a Cyran, Clemens C |b 13 |
| 700 | 1 | _ | |a Werner, Rudolf A |b 14 |
| 700 | 1 | _ | |a Fendler, Wolfgang P |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Casuscelli, Jozefina |b 16 |
| 700 | 1 | _ | |a Unterrainer, Lena M |b 17 |
| 773 | _ | _ | |a 10.1007/s00259-025-07674-5 |0 PERI:(DE-600)2098375-X |p nn |t European journal of nuclear medicine and molecular imaging |v nn |y 2025 |x 1619-7070 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:306585 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 0000-0002-9234-0795 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-05 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-05 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2022 |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-05 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-05 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-05 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2022 |d 2024-12-05 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|